Arcturus Therapeutics Holdings Inc's Comment on Supply Chain
The company has manufactured and supplied gram quantities of drug substance and scaled-up finished drug products, including a COVID vaccine, through their contract development and manufacturing organizations (CDMOs) for clinical studies and commercial readiness. They have established sufficient manufacturing capacity through their CDMOs to support internal research, development, potential commercial needs, and obligations under existing agreements. The company continues to evaluate relationships with additional suppliers to increase capacity and diversify the supply chain. A key collaboration is with CSL Seqirus, with whom the company has a global exclusive agreement for the research, development, manufacturing, and commercialization of self-amplifying mRNA vaccines targeting SARS-CoV-2, influenza, and three other infectious diseases. CSL Seqirus holds rights to the company's STARR mRNA technology, LUNAR lipid-mediated delivery system, and manufacturing expertise. The company received an upfront payment and potential milestone payments from CSL Seqirus and is entitled to a share of net profits and royalties from vaccine sales.
Arcturus Therapeutics Holdings Inc's Comment on Supply Chain
The company has manufactured and supplied gram quantities of drug substance and scaled-up finished drug products, including a COVID vaccine, through their contract development and manufacturing organizations (CDMOs) for clinical studies and commercial readiness. They have established sufficient manufacturing capacity through their CDMOs to support internal research, development, potential commercial needs, and obligations under existing agreements. The company continues to evaluate relationships with additional suppliers to increase capacity and diversify the supply chain. A key collaboration is with CSL Seqirus, with whom the company has a global exclusive agreement for the research, development, manufacturing, and commercialization of self-amplifying mRNA vaccines targeting SARS-CoV-2, influenza, and three other infectious diseases. CSL Seqirus holds rights to the company's STARR mRNA technology, LUNAR lipid-mediated delivery system, and manufacturing expertise. The company received an upfront payment and potential milestone payments from CSL Seqirus and is entitled to a share of net profits and royalties from vaccine sales.
Sources:
Arcturus Therapeutics Holdings Inc 's official press releases and regulatory filings; CSIMarket.com's supply-chain research; and the financial filings and press releases of other companies cited in this report.
Updated on:
For your research, we’ve provided nine additional tables on Arcturus Therapeutics Holdings Inc ’s suppliers.
You can find them in the navigation menu under Suppliers.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
